
Switzerland · Research startup
CDR-Life Inc. is a Swiss biotherapeutics company founded in 2017 and based in Schlieren, Zurich.
Funding reportedLast round: Series A
CDR-Life Inc. is a Swiss biotherapeutics company founded in 2017 and based in Schlieren, Zurich.
The company focuses on developing next-generation immunotherapies for cancer and autoimmune diseases. Led by CEO Christian Leisner and co-founders Dominik Escher and Konstantin von Schulthess, CDR-Life aims to create therapies that precisely target tumor cells while minimizing effects on healthy tissue. The company's core technology, the M-gager® platform, enables the development of highly selective T-cell engagers that target intracellular tumor antigens. This innovative approach allows for the creation of first-in-class immunotherapies for both solid tumors, such as lung and breast cancer, and liquid tumors like multiple myeloma. CDR-Life is currently advancing several investigational drug candidates, with two already in human testing. The company has also established strategic collaborations, including a partnership with Boehringer Ingelheim for an antibody fragment therapy targeting macular degeneration.
Funding, as reported
From CDR-Life Inc.'s own website: 5 founders, 7 on the team.
What they build
Known for
health careantibody humanizationbiotechnology researchbispecific tcesantigen-specific t cell activationmhc targetingmedical researchimmune system activationbispecific antibodiesautoimmune cell targetingindication-specific therapieshospital & health careantibody stabilitytarget-specific therapyautoimmune treatmentcancer immunotherapy
Built with from their website
Yoast SEOGoogle MapsContact Form 7Google Tag ManagerWordPress.orgPWAFont AwesomeApacheViewport MetaYoast
Google AnalyticsCloudflare Rocket LoaderGoogle Analytics 4WordpressMicrosoft Exchange OnlinejQuery MigrateGoogle Maps PlatformPriority Hints
Add your raise, your deck and your story, and put CDR-Life Inc. in front of investors. Or tell us what we have wrong.